Curing HCV in Treatment-Naïve Patients With Early Stage Liver Disease: Considerations for Treatment Selection, Monitoring, and Follow-Up
Developed in collaboration
Paul Y. Kwo, MD
Professor of Medicine
Chief of Hepatology
Sara C. Miller, MS
Director, QI Institute, CE Strategy and Content
Compliance and Meeting Planning Specialist
Indiana University School of Medicine
Upon completion, participants should be able to:
- Outline therapeutic options and expected outcomes in treatment-naïve patients with HCV infection and early stage liver disease
This activity is intended for primary care clinicians.
Statement of Need
In a single county in Indiana, more than 200 patients have been newly diagnosed with HIV since 2014; 95% of these individuals are coinfected with hepatitis C virus (HCV). This rapid spread of infectious disease is due to injection drug use (IDU) of prescription opiates in a rural area with limited healthcare resources, which highlights the need for proactive and innovative healthcare. Experts do not believe that this scenario is limited to just this one county. Indeed, increased rates of HCV infection have been documented across the country. However, newer direct-acting antiviral therapies for the treatment of HCV have revolutionized care and make achieving a sustained viral response—a functional cure for HCV—an attainable possibility for almost all individuals with chronic HCV infection. Reducing the burden of HCV has important implications on an individual level and is a critical public health need.
This activity was developed in collaboration with Indiana University School of Medicine and Med-IQ.
Joint Accreditation Statement
In support of improving patient care, Indiana University School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Indiana University School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses, nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Instructions to Receive Credit
To receive credit, read the introductory CME material, listen to the audiocast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: October 1, 2018
Expiration Date: September 30, 2019
Estimated Time to Complete This Activity: 30 minutes
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Indiana University School of Medicine and Med-IQ require any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Paul Y. Kwo, MD
Consulting fees/advisory boards: AbbVie Inc., Gilead Sciences, Inc., Merck & Co., Inc.
The peer reviewers and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
For more information about other Indiana University programs, please visit: http://cme.medicine.iu.edu.
Operating system - Med-IQ supports the following operating systems:
- Microsoft Windows supported by Microsoft
- Mac OS supported by Apple
Browsers - Med-IQ supports the current version of each browser listed below, plus two prior versions:
Microsoft Internet Explorer
- Microsoft Edge
Operating system - Med-IQ supports the current operating system, plus two prior releases:
- Android (eg, Samsung Galaxy)
- Apple (eg, iPhone/iPad)
Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
- Android (Chrome)
- Apple (Safari)
Applications & Software
PDF Viewer - Adobe Acrobat Reader or Adobe Reader
Adobe Flash Player - Med-IQ supports the current version, plus two prior versions
For technical assistance, please refer to our Support Manual.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Acknowledgment of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Gilead Sciences, Inc.
© 2018 The Indiana University School of Medicine
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.